ישראל - עברית - Ministry of Health

novartis pharma services ag - methylergometrine maleate 125 mcg - tablets - methylergometrine - prevention or treatment of uterine haemorrhage.

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

ישראל - עברית - Ministry of Health

gramse pharmaceuticals ltd - acetylsalicylic acid 325 mg - tablets enteric coated - acetylsalicylic acid - analgetic,antipyretic.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - potassium chloride 600 mg - tablets slow release - potassium chloride - treatment and prevention of hypokalaemia.

ישראל - עברית - Ministry of Health

novartis pharma services ag - terbinafine hydrochloride 281.25 mg - tablets - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum. oral lamisil should only be used to treat extensive, severe ringworm infections ( tinea corporis, tinea cruris and tinea pedis). oral lamisil is not effective against vaginal candidiasis or pityriasis (tinea) versicolor. onychomycoses ( tinea unguium, ringworm of the nails) due to infecton with dermatophyte organisms ( hyphomycetes).

ישראל - עברית - Ministry of Health

novartis pharma services ag - everolimus 0.1 mg - tablets dispersible - everolimus - kidney and heart transplantationcertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

ישראל - עברית - Ministry of Health

novartis pharma services ag - everolimus 0.25 mg - tablets dispersible - everolimus - kidney and heart transplantationcertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.